[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507037":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":30,"responsibleParty":61,"collaborators":63,"id":72,"slug":10,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":80,"minAge":81,"maxAge":10,"enrollmentInfo":82,"targetDuration":10,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Meir Medical Center","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"OHI+ patients",null,"Adult patients with hematologic malignancies that have sCD25\\>3,900 U\u002FmL and ferritin \\>1,000 ng\u002FmL",{"label":13,"type":10,"description":14,"interventionNames":10},"OHI- patients","Adult patients with hematologic malignancies, with sCD25\\>3,900 U\u002FmL and\u002For ferritin \\\u003C 1,000 ng\u002FmL",[16],{"name":17,"affiliation":5,"role":18},"Adi Zoref-Lorenz","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Adi Zoref Lorenz, MD","CONTACT","513 6525610","adi.zoref.lorenz@cchmc.org",{"name":26,"role":22,"phone":27,"phoneExt":28,"email":29},"Noa Rabinowicz, PhD","+972-54-4864564","+972-9-7472398","noa.rabinowicz@clalit.org.il",[31,47],{"facility":5,"status":32,"city":33,"state":10,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Kfar Saba","4428164","Israel",{"type":37,"coordinates":38},"Point",[39,40],34.90694,32.175,{"lat":40,"lon":39},[43],{"name":44,"role":22,"phone":45,"phoneExt":10,"email":46},"Uri Abadi, MD","+972 537482629","uri.abadi@clalit.org.il",{"facility":48,"status":32,"city":49,"state":10,"zip":50,"country":35,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Rabin Medical Center","Petah Tikva","49100",{"type":37,"coordinates":52},[53,54],34.88747,32.08707,{"lat":54,"lon":53},[57],{"name":58,"role":22,"phone":59,"phoneExt":10,"email":60},"Ronit Gurion, MD","+972 504065336","ronitg@clalit.org.il",{"type":62,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[64,66,67,70],{"name":65,"class":6},"Children's Hospital Medical Center, Cincinnati",{"name":48,"class":6},{"name":68,"class":69},"Sheba Medical Center","OTHER_GOV",{"name":71,"class":6},"Schneider Children's Medical Center, Israel","100507037",false,"NCT05882175","Prospective Validation of the OHI Index","A Prospective Study to Validate the Prognostic Power of the Optimized HLH Inflammatory (OHI) Index","HLH","Inclusion Criteria:\n\n* Patients with hematologic malignancies\n* At least 18 years old\n\nExclusion Criteria:\n\n* Prior recent treatment (chemotherapy\u002F other cytoreductive therapies in the last month)",true,"ALL","18 Years",{"count":83,"type":84},300,"ESTIMATED","OBSERVATIONAL","Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \\> 3,900 U\u002FmL and ferritin \\>1,000 ng\u002FmL . However, the true incidence and outcomes of HLH\u002FOHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.",[77,88,89,90,91],"Hemophagocytic Lymphohistiocytoses","Hemophagocytic Syndrome","Hematologic Malignancy","Hematologic Neoplasms","2025-05-08",{"date":94,"type":95},"2025-05-13","ACTUAL",{"date":97,"type":95},"2021-03-03",{"date":99,"type":84},"2030-03-03",{"name":5,"class":6},2]